Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver diseaseMaria Kjærgaard, Aleksander Krag, Katrine Prier Lindvig et al.|Journal of Hepatology|2023Cited by 213
Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort studyMads Israelsen, Aleksander Krag, Charlotte Wilhelmina Wernberg et al.|The Lancet. Gastroenterology & hepatology|2024Cited by 152
Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver diseaseDitlev Nytoft Rasmussen, Maja Thiele, Stine Johansen et al.|Journal of Hepatology|2021Cited by 141
Effect of Calorie-Unrestricted Low-Carbohydrate, High-Fat Diet Versus High-Carbohydrate, Low-Fat Diet on Type 2 Diabetes and Nonalcoholic Fatty Liver DiseaseCamilla Dalby Hansen, Aleksander Krag, Eva-Marie Gram-Kampmann et al.|Annals of Internal Medicine|2022Cited by 110
Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trialMads Israelsen, Bjørn Stæhr Madsen, Nikolaj Torp et al.|The Lancet. Gastroenterology & hepatology|2023Cited by 74